Contineum Therapeutics (CTNM) Cash from Financing Activities (2023 - 2026)

Contineum Therapeutics' Cash from Financing Activities history runs 4 years deep, the most recent figure standing at $129000.0 for Q1 2026.

• On a quarterly basis, Cash from Financing Activities rose 437.5% year-over-year to $129000.0 in Q1 2026; TTM through Mar 2026 was $112.8 million, a 3.44% increase from a year earlier, with the FY2025 full-year figure at $112.7 million, up 3.38% from the prior year.
• Cash from Financing Activities fell to $129000.0 in Q1 2026 per CTNM's latest filing, from $93.5 million in the prior quarter.
• Across five years, Cash from Financing Activities topped out at $108.4 million in Q2 2024 and bottomed at -$617000.0 in Q1 2023.
• The 4-year median for Cash from Financing Activities is $129000.0 (2026), against an average of $21.4 million.
• Biggest YoY gain for Cash from Financing Activities was 146861.54% in 2025; the steepest drop was 99.92% in 2025.
• Year by year, Cash from Financing Activities stood at -$321000.0 in 2023, then surged by 300.0% to $642000.0 in 2024, then surged by 14458.41% to $93.5 million in 2025, then tumbled by 99.86% to $129000.0 in 2026.
• Per Business Quant, the three latest CTNM Cash from Financing Activities figures stand at $129000.0 (Q1 2026), $93.5 million (Q4 2025), and $19.1 million (Q3 2025).